Key Points
- AbbVie EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81% to 83,171 shares.
- AbbVie reported quarterly EPS of $3.82, beating estimates, while revenue rose 10.3% year over year to $17.4 billion; it also raised its quarterly dividend from $1.73 to $1.82 per share.
- Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $297.46.
AbbVie Inc. (NYSE:ABBV - Get Free Report) EVP Jeffrey Stewart sold 40,619 shares of the business's stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company's stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
AbbVie Trading Down 0.1%
ABBV stock opened at $294.75 on Friday. The firm has a market cap of $521.01 billion, a P/E ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93. The stock's 50 day simple moving average is $274.82 and its 200 day simple moving average is $240.55.
AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analysts' expectations of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted $1.86 earnings per share. On average, research analysts forecast that AbbVie Inc. will post 13.98 EPS for the current fiscal year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a positive change from AbbVie's previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie's dividend payout ratio is currently 119.10%.
Hedge Funds Weigh In On AbbVie
Several institutional investors have recently modified their holdings of the company. Financial Freedom LLC acquired a new position in AbbVie during the 3rd quarter valued at about $29,000. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter worth about $30,000. Marquette Asset Management LLC grew its position in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after purchasing an additional 48 shares during the last quarter. IMG Wealth Management Inc. increased its stake in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after purchasing an additional 153 shares during the period. Finally, Principia Wealth Advisory LLC increased its stake in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after purchasing an additional 44 shares during the period. Institutional investors own 70.23% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on ABBV shares. Guggenheim lifted their price target on shares of AbbVie from $288.00 to $322.00 and gave the company a "buy" rating in a report on Monday, November 2nd. Royal Bank Of Canada increased their price objective on shares of AbbVie from $280.00 to $330.00 and gave the stock an "outperform" rating in a research note on Monday, November 2nd. BMO Capital Markets set a $315.00 price target on AbbVie in a research report on Wednesday, November 4th. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. Finally, Rothschild & Co Redburn boosted their price objective on AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $297.46.
Check Out Our Latest Stock Report on ABBV
AbbVie News Summary
Investors following ABBV have been watching these news items:
- Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
- Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update
- Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing
About AbbVie
(
Get Free Report)
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
